All articles tagged with #healthpharmaceuticals
Eli Lilly is funding studies to show that its weight loss drug Zepbound can also treat sleep apnea, aiming to convince insurers to cover the medication. The company has submitted promising study results to the FDA to expand the drug's approved uses beyond weight loss and diabetes, hoping to build a stronger case for broader insurance coverage.
The FDA's expanded approval of Sarepta Therapeutics' Duchenne muscular dystrophy drug, Elevidys, allows the company to sell the gene therapy with minimal restrictions, potentially benefiting patients but raising concerns about the FDA's decision-making process.
Insmed's experimental drug brensocatib successfully reduced lung problems in bronchiectasis patients during a Phase 3 trial, leading to a significant increase in the company's share price. Both tested dosages of the drug met the primary endpoint by reducing pulmonary exacerbations by about 20% compared to placebo, with analysts predicting potential billion-dollar annual sales if approved.
In the early 2000s, major pharmaceutical companies faced a decline in psychiatric drug innovation as their blockbuster treatments for depression and schizophrenia neared generic status. This led to a shift away from mental health research in favor of other therapeutic areas. However, there is now optimism for a resurgence in neuroscience-driven drug development, offering hope for new and improved psychiatric medicines.